Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma
JAMA Network Open · 10.03.2023 · 6 (3) · e232526
DOI: 10.1001/jamanetworkopen.2023.2526 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 10.03.2023. Verfasst von Melina E Marmarelis und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania Health System, Philadelphia. Hauptthemen laut MEDLINE: Mesothelioma, Malignant, Mesothelioma, Peritoneal Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Importance Diffuse malignant peritoneal mesothelioma (DMPM) represents a rare and clinically distinct entity among malignant mesotheliomas. Pembrolizumab has activity in diffuse pleural mesothelioma but limited data are available for DMPM; thus, DMPM-specific outcome data are needed.
Objective
To evaluate outcomes after the initiation of pembrolizumab monotherapy in the treatment of adults with DMPM. Design, Setting, and Participants This retrospective cohort study was conducted in 2 tertiary care academic cancer centers (University of Pennsylvania Hospital Abramson Cancer Center and Memorial Sloan Kettering Cancer Center). All patients with DMPM treated between January 1, 2015, and September 1, 2019, were retrospectively identified and followed until January 1, 2021. Statistical analysis was performed between September 2021 and February 2022. Exposures Pembrolizumab (200 mg or 2 mg/kg every 21 days). Main Outcomes and Measures Median progression-free survival (PFS) and median overall survival (OS) were assessed using Kaplan-Meier estimates. The best overall response was determined using RECIST (Response Evaluation Criteria in Solid Tumors) criteria, version 1.1. The association of disease characteristics with partial response was evaluated using the Fisher exact test.
Results
This study included 24 patients with DMPM who received pembrolizumab monotherapy. Patients had a median age of 62 years (IQR, 52.4-70.6 years); 14 (58.3%) were women, 18 (75.0%) had epithelioid histology, and most (19 [79.2%]) were White. A total of 23 patients (95.8%) received systemic chemotherapy prior to pembrolizumab, and the median number of lines of prior therapy was 2 (range, 0-6 lines). Of the 17 patients who underwent programmed death ligand 1 (PD-L1) testing, 6 (35.3%) had positive tumor PD-L1 expression (range, 1.0%-80.0%). Of the 19 evaluable patients, 4 (21.0%) had a partial response (overall response rate, 21.1% [95% CI, 6.1%-46.6%]), 10 (52.6%) had stable disease, and 5 (26.3%) had progressive disease (5 of 24 patients [20.8%] were lost to follow-up). There was no association between a partial response and the presence of a BAP1 alteration, PD-L1 positivity, or nonepithelioid histology. With a median follow-up of 29.2 (95% CI, 19.3 to not available [NA]) months, the median PFS was 4.9 (95% CI, 2.8-13.3) months and the median OS was 20.9 (95% CI, 10.0 to NA) months from pembrolizumab initiation. Three patients (12.5%) experienced PFS of more than 2 years. Among patients with nonepithelioid vs epithelioid histology, there was a numeric advantage in median PFS (11.5 [95% CI, 2.8 to NA] vs 4.0 [95% CI, 2.8-8.8] months) and median OS (31.8 [95% CI, 8.3 to NA] vs 17.5 [95% CI, 10.0 to NA] months); however, this did not reach statistical significance. Conclusions and Relevance The results of this retrospective dual-center cohort study of patients with DMPM suggest that pembrolizumab had clinical activity regardless of PD-L1 status or histology, although patients with nonepithelioid histology may have experienced additional clinical benefit. The partial response rate of 21.0% and median OS of 20.9 months in this cohort with 75.0% epithelioid histology warrants further investigation to identify those most likely to respond to immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania Health System, Philadelphia.
- Department of Radiology, University of Pennsylvania Health System, Philadelphia.
- Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Health System, Philadelphia.
- Department of Surgery, University of Pennsylvania Health System, Philadelphia.
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
- Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Förderung
- NCI NIH HHS
Zitieren
APA
Marmarelis, M. E., Wang, X., Roshkovan, L., Grady, C. B., Miura, J. T., Ginsberg, M. S., Ciunci, C. A., Egger, J., Walker, S., Cercek, A., Foote, M. B., Litzky, L. A., Nash, G., Haas, A. R., Karakousis, G. C., Cengel, K. A., Katz, S. I., Zauderer, M. G., Langer, C. J., & Offin, M. (2023). Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma. JAMA Network Open, 6(3), e232526. https://doi.org/10.1001/jamanetworkopen.2023.2526
Vancouver
Marmarelis ME, Wang X, Roshkovan L, Grady CB, Miura JT, Ginsberg MS, et al. Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma. JAMA Network Open. 2023;6(3):e232526. doi:10.1001/jamanetworkopen.2023.2526
BibTeX
@article{Marmarelis2023,
author = {Marmarelis, Melina E and Wang, Xiao and Roshkovan, Leonid and Grady, Connor B and Miura, John T and Ginsberg, Michelle S and Ciunci, Christine A and Egger, Jacklynn and Walker, Suzanne and Cercek, Andrea and Foote, Michael B and Litzky, Leslie A and Nash, Garrett and Haas, Andrew R and Karakousis, Giorgos C and Cengel, Keith A and Katz, Sharyn I and Zauderer, Marjorie G and Langer, Corey J and Offin, Michael},
title = {Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma},
journal = {JAMA Network Open},
year = {2023},
volume = {6},
number = {3},
pages = {e232526},
doi = {10.1001/jamanetworkopen.2023.2526}
}
EUVIMED